2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
April 17, 2018
By: Ross Blau
Westlaw Journal
Ross Blau co-authored, "2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways" with Jonathan Harris and Drew Hillier which was published by Westlaw Journal Medical Devices, Westlaw Journal Products Liability, Westlaw Journal Health Law, Westlaw Journal Pharmaceutical and Westlaw Journal Intellectual Property. The article discusses nuanced shifts in Federal Circuit opinions and the lessons that can be gleaned from them.
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Concurrences New Frontiers of Antitrust Conference 2026
Sponsorship
Antitrust
Stakeholders 26th Annual CYOC Conference
Event
Antitrust
ALFDP 20th Anniversary Annual Conference
Event
Antitrust
GCR Live: Women in Antitrust 2026
Sponsorship
Antitrust
GICLI Annual Meeting 2026
Sponsorship
Antitrust
Informa CompLaw Advanced EU Conference 2026
Sponsorship
Antitrust
Wild Tomorrow 2026 Annual Gala
Sponsorship
Antitrust
NAPABA Annual Convention 2026
Sponsorship
Antitrust
Law.com General Counsel Conference East 2026
Sponsorship
Antitrust
Economist Enterprise's 1st Annual Antitrust Summit US
Sponsorship
Antitrust
